

**14th WORLD CONGRESS ON HEART DISEASE** INTERNATIONAL ACADEMY OF CARDIOLOGY ANNUAL SCIENTIFIC SESSIONS 2008 TORONTO, ON, CANADA, JULY 26 -29, 2008

## PRELIMINARY LIST OF SCIENTIFIC PRESENTATIONS

## NEW THERAPEUTIC TARGETS IN CARDIOVASCULAR MEDICINE

Protein Kinase C Isozymes in Heart Disease: A Therapeutic Opportunity *Daria Mochly-Rosen,* Stanford University, Palo Alto, CA, USA

Renin Inhibition: A Novel Approach to Blood Pressure Control and Organ Protection *Alexander H. J. Danser*, Erasmus Medical Center Rotterdam, The Netherlands

RHO-Kinase is an Important Therapeutic Target in Cardiovascular Medicine *Hiroaki Shimokawa*, Tohoku University Graduate School of Medicine, Sendai, Japan

Inhibition of Phospholipases: A New Strategy to Treat Atherosclerosis and its Clinical Complications? *Wolfgang Koenig*, University of Ulm Medical Center, Ulm, Germany

Peptidases Degrading Cardioprotective Natriuretic Peptides: A New Target for the Treatment of Cardiovascular Diseases? Thomas Walther, Charite-Universitatsmedizin, Berlin, Germany

Coronary Microvascular Regulation by Angiotensin II: Pathophysiological Implications *Lih Kuo*, Temple Cardiovascular Research Institute Texas, TX, USA

Inhibiting Malonyl COA Decarboxylase as an Approach to Treating Ischemic Heart Disease Gary Lopaschuk, University of Alberta Edmonton AB, Canada

Role of Sarcoplasmic Reticulum in Increasing Intracellular CA2+ due to NA+-K+ ATPASE inhibition by Ouabain *Harjot K. Saini-Chohan*, University of Manitoba, Winnipeg, Canada

# ENDOTHELIAL BIOMEDICINE: NEW OPPORTUNITIES FOR DIAGNOSIS AND TREATMENT

Restoration of Endothelial Function by Statins and Beta-Blockers *Tadeusz Malinski*, Ohio University, Athens, OH, USA

The Role of Endothelial Progenitor Cells In Cardiovascular Diseases *Dimitris Tousoulis*, Hippokration Hospital, Athens, Greece

**Does Tissue Factor Link Vasospasm And Thrombosis** *Felix C. Tanner*, Cardiovascular Research Physiology Institute & Clinic for Cardiology, University of Zurich, Zurich, Switzerland

Contributions of Endoplasmic Reticulum (ER) to Cardiovascular Disease *Richard C. Austin*, Henderson Research Center, Hamilton, ON, Canada

Coronary Endothelial Dysfunction in Left Ventricular Hypertrophy Louis P. Perrault, Montreal Heart Institute, Montreal, Canada

Endothelium, Inflammation and Vascular Aging Carlos F. Sanchez Ferrer, Universidad Autonoma de Madrid, Madrid, Spain

## ENDOTHELIAL BIOMEDICINE: NEW OPPORTUNITIES FOR DIAGNOSIS AND TREATMENT (continued)

Insulin Resistance – Effects on Vascular Endothelial Function and Repair *Stephen Wheatcroft,* University of Leeds, Leeds, UK

#### Endothelium in the Heart

Suresh C. Tyagi, University of Louisville, KY, USA

## NOVEL BIOMARKERS AND MOLECULAR TARGETS

## New Plaque Biomarkers for Atherosclerotic Disease Progression: Outcome of the Longitudinal Athero-Express Study *Gerard Pasterkamp*, University Medical Center, Utrecht, The Netherlands

Serum Amyloid A: A Marker and Mediator of Acute Coronary Syndromes *Janos G. Filep*, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada

Cardiac Biomarkers in Pulmonary Embolism and Lung Disease Ijaz Khan, University of Maryland School of Medicine, Baltimore, MD, USA

## THE RELEVANCE OF GENETICS IN PROVIDING AN UNDERSTANDING OF CARDIOVASCULAR DISEASES

Genetics of Coronary Artery Disease in Families Lewis C. Becker, Johns Hopkins University School of Medicine. Baltimore, MD, USA

Genetic Basis of Polygenic Hypertension from Animal Models to Humans Alan Y. Deng, Research Center- CHUM, Montreal, QC, Canada

Genetics of Myocardial Infarction *Robert Roberts*, University of Ottawa Heart Institute, Ottawa, ON, Canada

Finding and Validating New Targets for Heart Failure Treatment Burns C. Blaxall, University of Rochester Medical Center, Rochester, NY, USA

Getting to the Point: Forkhead Transcription Factors in the Vascular System *Kenneth Maiese*, Wayne State University School of Medicine, Michigan, Detroit, USA

Nucleic Acid Based Gene Targeting: Current Status in Cardiovascular Medicine *Harry C. Lowe*, University of Sydney, Sydney, NSW, Australia

#### **Pharmacogenetics**

Harisios Boudoulas, Center for Clinical Research Academy of Athens, Greece

Identification of MI-Susceptibility Genes using Genome-Wide Linkage Analysis *Mitsuhiro Yokota*, Aichi-Gakuin University, Nagoya, Japan

Cardiac Hypertrophy and Pro-Inflammatory Cytokines in Npr1 Gene-Disrupted Mouse Model

Kailash N. Pandey, Tulane University School of Medicine, New Orleans, LA, USA

The Role of Phospholipase C in Cardiac Hypertrophy Paramjit S. Tappia, Faculty of Medicine, University of Manitoba, Canada

Functional Corin Gene Mutations and the Risk of Hypertension, LVH, and Progression of Systolic Heart Failure in African-Americans Daniel L. Dries, University of Pennsylvania, PA, USA

#### **CARDIAC REPAIR AND REGENERATION**

Novel Myogenesis Strategies Roger Laham, Harvard Medical School, Boston, MA, USA

Mesenchymal Stromal Cell Therapy in Heart Disease Jens Kastrup, University Hospital Rigshospitalet, Copenhagen, Denmark

In Situ Tissue Engineering For the Treatment of Cardiomyopathy *Randall J. Lee*, University of California, San Francisco, CA, USA

The Role of Endothelial Progenitor Cells in Atherosclerosis and Coronary Artery Disease *Shing- Jong Lin*, Taipei Veterans General Hospital, Taipei, Taiwan-R.O.C.

#### ATHEROGENESIS, INFLAMMATION AND OXIDATIVE STRESS

Regulation of Intracellular Calcium in the Ischemic Heart Disease Naranjan S. Dhalla, St Boniface Hospital Research Centre, Winnipeg, MB, Canada

What is More Important in Atherogenesis- Oxidized or Native - LDL Jawahar L. Mehta, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Stress and CV Disease - Oxidative and Otherwise Philip R. Liebson, Rush University Medical Center, Chicago, IL, USA

II-10 and TNF- A Cykotine Imbalance in Heart Failure Pawan K.Singal, Institute of Cardiovascular Sciences, MB, Canada.

The Metabolic Syndrome, Oxidative Stress and Inflammation, and Cardiovascular Diseases *Paul Holvoet*, Katholieke Universiteit Leuven, Belgium

Noxes, Oxidative Stress and Cardiovascular (PATHO) Biology Rhian M. Touyz, University of Ottawa, ON, Canada

Analysis of Molecular Inflammatory Pathways in Atherogenesis Salomon Amar, Boston University, Boston, MA, USA

Role of NADPH Oxidase in Human Atherosclerosis Francesco Violi, Universita di Roma La Sapienza, Rome, Italy

Inflammation and Metabolic Disorders *Guo-Ping Shi*, Harvard Medical School, Boston, MA, USA

Drugs Preventing Vascular Oxidative Stress: Reciprocal Regulation of Pro- and Anti-Oxidative Enzyme Systems *Ulrich Forstermann*, Johannes Gutenberg University, Mainz, Germany

Modulation of Vascular Inflammation and Stabilization of Atherosclerotic Plaque Phenotype by Sirolimus *Domenico Pratico*, Temple University, Philadelphia, PA, USA

Oxidative Stress & Atherogenesis – The Role of Drugs with Antioxidant Capacity *Jaw-Wen Chen,* National Yang-Ming University School of Medicine; Taiwan, Taipei

Inflammation In Diabetic Vascular Disease : The Role Of Hypoglycemia Concepcion Peiro, Universidad Autonoma de Madrid, Arzobispo Morcillo, Madrid, Spain

#### MODULATION OF ISCHEMIA-REPERFUSION INJURY

Potential Effects of Anti-Platelet Therapy on the Pleiotropic Effects of Statins *Yochai Birnbaum*, University of Texas Medical Branch, Galveston, TX, USA

The Role of the Chemokines in Healing Myocardial Infarction Nikolaos Frangogiannis, Baylor College of Medicine, Houston, TX, USA

Cytochrome P450 Enzymes in Heart Disease Ingrid Fleming, Klinikum der J.W. Goethe-Universitat, Frankfurt, Germany

Fetal Programming Increases Cardiac Susceptibility to Ischemia/Reperfusion Injury Sandra T. Davidge, University of Albert, Edmonton, AB, Canada

Aging-Reduced Myocardial Insulin Sensitivity Contributes to the Aggravated Myocardial Injury Following Myocardial Ischemia/Reperfusion *Feng Gao*, Fourth Military Medical University, Xian, Xian, China

#### NANOMEDICINE AND MOLECULAR IMAGING

Nanomedicine: The Next Frontier in Clinical Cardiology Israel Rubinstein, University of Illinois College of Medicine, Chicago, IL, USA

Macrophage Activation and Atherogenesis: Basic Biology and Molecular Imaging *Masanori Aikawa*, Brigham and Women's Hospital, Boston, MA, USA

Imaging Mechanisms of Arterial Calcification in Atherosclerosis and Chronic Kidney Disease *Elena Aikawa*, Center for Molecular Imaging Research, Charleston, MA, USA

Metabolic Imaging of the Heart: Ischemic Memory Vasken Dilsizian, University of Maryland School of Medicine, Baltimore, MD, USA

New CT Imaging Targets of Vulnerable Plaque

Birgit Kantor, Mayo Clinic, Rochester, MN, USA

## **NEWER ECHOCARDIOGRAPHIC TECHNIQUES**

Newer Echocardiographic Methods for Cardiovascular Phenotyping in Small Animals *Brian D. Hoit,* Case Western Reserve University, Cleveland, OH, USA

Clinical Application of 3D Echocardiography Takahiro Shiota, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

Noninvasive Assessment of Left Ventricular Systolic Torsion: Is it Time to do the Twist? Jonathan N. Bella, Bronx -Lebanon Hospital Center, NY, USA

**Coronary Flow Reserve in the Echo Lab: Prognostic Impact** *Rosa Sicari*, CNR Institution of Clinical Physiology, Pisa, Italy

New Innovations in Echocardiography Smadar Kort, Stony Brook University Medical Center, NY, USA

New Aspects of Ultrasound Contrast in Cardiology Annemieke Jansen, Canisius Wilhelmina Hospital, Nijmegen, Netherlands

Stress EchoCardiography for Risk Stratification *Abdou Elhendy,* Marshfield, WI USA

Non-Invasive Assessment of Vascular Load and Ventricular-Vascular Coupling: A Focus on Echocardiography Julio A. Chirinos, Philadelphia VA Medical Center, PA, USA

#### **IDENTIFICATION OF HIGH RISK ASYMPTOMATIC PATIENTS**

Targeting the High Risk Asymptomatic Patient for Therapy: The Role of Cardiac Imaging beyond Coronary Risk Factors *Ronald G. Schwartz*, University of Rochester Medical Center, Rochester, NY, USA

Myocardial Viability Diagnosis and Risk Stratification Faroog A. Chaudhry, St. Luke's Roosevelt Hospital Center, New York, NY, USA

Infarct Sizing By Spect J. Wells Askew, Mayo Clinic, Rochester, Minnesota, USA

The Prognostic Value of CT Coronary Calcification in Asymptomatic Individuals *Michael Motro*, Chaim Sheba Medical Center, Tel Hashomer, Israel

Incremental Value of CT to SPECT in Patient Management John J. Mahmarian, Baylor College of Medicine, Houston, TX, USA

Detection of Coronary Artery Disease with Dipyridamole Stress Michael Main, Mid America Heart Institute, Kansas City, MO, USA

Subclinical Cardiovascular Disease: What Does It Mean? Michael H. Criqui, University of California, CA, USA

Atherosclerotic Calcification – The Cardiovascular Epidemiology of Whole Body Scanning Matthew Allison, University of California San Diego, La Jolla, CA, USA

## **UPDATE ON MAGNETIC RESONANCE IMAGING**

Is There a Role for CMR in Cardiology Practice? Gerald Pohost, Salick Cardiovascular Centers, Los Angeles, CA, USA

Diagnostic and Prognostic Value of Delayed-Enhancement Magnetic Resonance Imaging

Rungroj Krittayaphong, Siriraj Hospital Mahidol University, Bangkok, Thailand

Atherosclerosis Imaging: A CT/MR Perspective Sanjay Rajagopalan, Ohio State University, Columbus, OH, USA

MRI Coronary Angiography in the Diagnosis of Anomalous Origin of the Coronary Arteries: A Comparison with Multi Detector Computed Tomography (MDCT) Sergio Dalla-Volta, Universita degli Studi di Padova, Padova, Italy

Prognostic Value of Cardiovascular Magnetic Resonance Imaging in Patients with Ischemic Heart Disease *Vicente Bodi*, Hospital Clinico Universitario, Valencia, Spain

MRI in Cardiac Electrophysiology Nassir Marrouche, University of Utah Health Sciences Center, Salt Lake City, UT, USA

#### INSIGHT INTO THE TREATMENT OF ACUTE CORONARY SYNDROMES

Outcome of Patients with Suspected ACS and Elevated Troponin without Significant Epicardial CAD *Nasser Lakkis*, Ben Taub General Hospital, Houston, TX, USA

Targeted Use of Drug-Eluting Stents: Lesions from the Basket Trial Hans Peter Brunner-La Rocca, University Hospital Basel, Basel, Switzerland

Troponin - From Molecular Alterations to Clinical Implications Dan Atar, University of Oslo, Oslo, Norway

Pro-Healing Aspects of 17B-Estradiol after PCI Jean-Francois Tanguay, Montreal Heart Institute, Montreal, Canada

Micro and Macrovascular Protection in Primary PCI Deepak Jain, Medizinische Klinik II, Lubeck, Germany

Integration of New Technologies in the Management of Cardiovascular Disease: What Have We Learned? Andrew J. Carter, Michigan State University School of Medicine, Kalamazoo, MI, USA

Are Platelet Inhibition, Coronary Flow, and Myocardial Perfusion Important Targets in NSTE-ACS Patients? *Leonardo Bolognese*, Azienda Ospedaliera Arezzo, Italy

The Role of Enoxaparin in Patients with Primary PCI for ST Elevation Myocardial Infarction *Uwe Zevmer*, Mediznische Klinik B, Ludwigshafen, Germany

#### INSIGHT INTO THE TREATMENT OF ACUTE CORONARY SYNDROMES (continued)

Does Intracoronary Therapy with Metabolic Cytoprotectors Limit Myocardial Injury in Patients with AMI? David G. losseliani, Moscow's City Center of Interventional Cardioangiology, Moscow,

**David G. Iosseliani**, Moscow's City Center of Interventional Cardioangiology, Moscow, Russia

### NEW DIRECTIONS IN CORONARY INTERVENTIONAL THERAPY

Low Level Laser Irradiation: Therapeutic Potential in Cardiovascular Pathology S. David Gertz, Hebrew University Hadassah Medical School, Jerusalem, Israel

Systemic Immunosuppression to Prevent Restenosis after Percutaneous Coronary Interventions to Cardiovascular Disease *Flavio Ribichini*, University of Verona, Italy

Neointima Coverage of DES and Risk of Stent Thrombosis - Angioscopic Evaluation *Yasunori Ueda*, Osaka Police Hospital, Osaka Japan

Update on Coronary Artery Bifurcation Lesions Classification and Interventional Technique *Mohammad-Reza Movahed*, University of Arizona Sarver Heart Center, AZ, USA

Intracoronary Pressure and Flow Velocity: Mechanistic Insight from Looking Beyond Means Maria Siebes, Academic Medical Center, Amsterdam, Netherlands

Sleeve Technique for the Stenting of Coronary Bifurcation Lesions Man-Hong Jim, Grantham Hospital, Hong Kong, China

Long-Term Safety and Effectiveness of Drug-Eluting Stents Jack V. Tu, Institute for Clinical Evaluative Sciences, Toronto, ON, Canada

#### **CAROTID ARTERY DISEASE: TREATMENT AND PREVENTION**

Carotid Artery Stenting 2008 – What do Trials and Registries Tell Us? *Harald Mudra*, Krankenhaus Munchen Neuperlach, Munchen, Germany

Carotid Angioplasty and Stenting under Protection. Complications, How to Avoid Them? *Michel Henry*, Cabinet de Cardiologie, Nancy Cedex, France

Elevated Levels of Troponin in Acute Ischemic Stroke – Silent Coronary Artery Disease?

Jesper Jensen, Odense University Hospital, Odense, Denmark

## EVOLVING TREATMENT STRATEGIES FOR ISCHEMIC CORONARY DISEASE

Update on Stable Angina with Special Emphasis on Management of "No Option" Angina Udho Thadani, University of Oklahoma HSC, Oklahoma City, OK, USA

Assessing Myocardial Ischemia in the Hypertensive Patient: Still a Challenge in Clinical Cardiology

Riccardo Bigi, University School of Medicine and CDI, Italian Diagnostic Center, Milan, Italy

The Left Atrium and its Role in Myocardial Ischemia Vignendra Ariyarajah, Boniface Hospital/University of Manitoba, Winnipeg, Canada

#### EPIDEMIOLOGY - CARDIOVASCULAR RISK ASSESSMENT

New Insights on Accelerated Vascular Calcification in Patients with Kidney Disease *Peter A. McCullough*, Beaumont Health Center, Royal Oak, MI, USA

Coffee and Coronary Disease Arthur L. Klatsky, Kaiser Permanente Medical Center, Oakland, CA, USA

Dietary Strategies for Hypertension Prevention: Progress and Promise Howard D. Sesso, Brigham & Women's Hospital, Boston, MA, USA

Influenza Vaccination: The Neglected Component of the Cardiovascular Prevention Guidelines Mohammad Madjid, Texas Heart Institute, Houston, TX, USA

Prediction of Cardiovascular Disease Takanobu Tomaru, Toho University Sakura Hospital, Sakura City, Chiba, Japan

Arterial Stiffness and Cardiovascular Risk Giuseppe Schillaci, University of Perugia Medical Hospital, Perugia, Italy

Second Hand Smoke and Cardiovascular Disease in Germany and Europe: A Sensitivity Analysis *Ulrich Keil*, University of Muenster, Muenster Germany

Circadian Aspects of Cardiovascular Diseases Roberto Manfredini, Hospital of Delta, Ferrara, Italy

#### DYSLIPIDEMIA AND CARDIOVASCULAR RISK

Intensive Statin Therapy in CHD - A Review of the Evidence *Kausik K. Ray,* University of Cambridge. Cambridge, England

Combination Therapy in Lipid Management Donna Polk, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Statins in the Elderly Dan Tzivoni, Shaare Zedek Medical Center, Jerusalem, Israel

New Targets for Cardiovascular Risk Reduction in the Metabolic Syndrome: Lipoproteins are more important than Lipids *Robert S. Rosenson*, University of Michigan, Ann Arbor, MI, USA

Protein Kinase A- Regulates Apolipoprotein E Secretion by Macrophages *Leonard Kritharides*, Concord Hospital, University of Sydney, Australia

HIV Protease Inhibitor Ritonanir Inhibits Cholesterol Efflux in Human Macrophages-Derived Foam Cells *Changyi Chen*, Baylor College of Medicine, Houston, TX, USA

### **HYPERTENSION**

A Guide to the New Guidelines for the Management of Hypertension *Clive Rosendorff*, Mt. Sinai School of Medicine and the J.J. Peters VA Medical Center, New York, NY, USA

The Role of Arterial Stiffness and Resistance in Hypertensive Cardiovascular Disease *Stanley S. Franklin*, University of California, CA, USA

### DIABETES, METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE

Metabolic Syndrome in Childhood and its Impact on Adult Heart Disease Gerald S. Berenson, Tulane Center for Cardiovascular Health, Louisiana, New Orleans, USA

Genetics and Metabolic Risk of Atherosclerosis Robert Hegele, University of Western Ontario, London, ON, Canada

Myocardial Ischemia-Reperfusion Injury in the Diabetic Heart Karin Przyklenk, University of Massachusetts Medical School, Worcester, MA, USA

The Utility of Spect Imaging in Asymptomatic Diabetic Patients Panithaya Chareonthaitawee, Mayo Clinic, Rochester, MN, USA

Tackling the Diabetic Platelet Dominick J. Angiolillo, University of Florida-Shands, Jacksonville, FL, USA

#### **CARDIOVASCULAR DISEASE IN WOMEN: CURRENT TRENDS**

Women and Heart Disease in the Post-WHI Era Elizabeth L. Barrett-Connor, University of California, San Diego, CA, USA

Heart Failure in Women: Really Different or Just PC? Maryl R. Johnson, University of Wisconsin Medical School, Madison, WI, USA

Dyslipidemia in Women: Epidemiology and Treatment Vera Bittner, University of Alabama at Birmingham, Alabama, USA

Estrogen, Aging and the Cardiovascular System Anne A. Knowlton, University of California, Davis, CA, USA

Outcomes for Women following Cardiac Surgery Veena Guru, Institute for Clinical Evaluative Sciences, Toronto, ON, Canada

Pregnancy and Heart Disease Candice Silversides, University Health Network, Toronto, ON, Canada

#### SPORTS AND CARDIOVASCULAR DISEASE

An Athlete's Heart may Harbour Proarrhythmic Changes Hein Heidbüchel, University Hospital Gasthuisberg, Leuven, Belgium

Exercise Training Improves Centrally Mediated Regulation of Sympathetic Outflow in Rats with Heart Failure *Kaushik P. Patel*, University of Nebraska Medical Center, Omaha, NE, USA

#### NOVEL PRACTICE AND PRACTICE ISSUES IN CARDIOLOGY

Update on Complementary and Integrative Therapies in Cardiovascular Disease *Maura Paul-Labrador*, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Unusual Presentations of Preload Dependent Cardiac Conditions and their Management *Hanumanth Reddy*, Medical Center of South Arkansas, El Dorado, AR, USA

## **AORTIC AND VASCULAR DISEASE**

A Blood Test for Thoracic Aneurysm John A. Elefteriades, Yale University School of Medicine, New Haven, CT, USA

Tissue Characterization in Renal Arteries Verghese Mathew, Mayo Clinic, Rochester, MN, USA

The Medical and Endovascular Therapy of SFA Disease Hitinder S. Gurm, University of Michigan, Ann Arbor, MI, USA

Intermittent Claudication: Walking Disability or Cardiovascular Disease? *Fabio Manfredini*, University of Ferrara Medical School, Ferrara, Italy

#### VALVULAR HEART DISEASE: EVALUATION AND TREATMENT

Biomarkers for Evaluating Valvular Diseases – Recent Progress Jeffrey S. Borer, Weill Medical College of Cornell University, NY, USA

The Concept of Valvulo-Metabolic Risk in Aortic Valve Disease *Philippe Pibarot*, Quebec Heart Institute, Sainte Foy, Quebec, Canada

Detection of Early Myocardial Dysfunction in Vavular Heart Disease *Ralph Stewart*, Auckland City Hospital, Auckland, New Zealand

Calcific Aortic Stenosis: Therapeutic Lessons Learned from Experimental Models *Nalini M. Rajamannan*, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Present Status of Rheumatic Heart Disease in Developing Countries of the World *Adarsh Kumar*, Govt. Medical College/G.N.D. Hospital, Amritsar, India

Percutaneous Aortic Valve Implantation: State of The Art Horst Sievert, Cardiovascular Center Frankfurt, Germany

Mitral Balloon Valvuloplasty – 18 years follow up: Effect on Left Ventricular Function, Severe Pulmonary Hypertension, and Severe Tricuspid Regurgitation *Mohamed E Fawzy*, King Faisal Specialist Hospital, Riyadh, Saudi Arabia

Transcatheter Closure of Perivalvular Leaks after Surgical Mitral and Aortic Valve Replacements *Larry Latson*, Children's Hospital at the Cleveland Clinic, Cleveland, OH, USA

Minimally Invasive Mitral Surgery: Should it be Considered State of the Art for Isolated Mitral Disease? *Francois Dagenais*, Laval Hospital, Quebec, Canada

## PEDIATRIC AND ADULT CONGENITAL HEART DISEASE MANAGEMENT

Quality Improvement in Pediatric Cardiology: An Overview of National Initiatives Geoffrey L. Rosenthal, Cleveland Clinic Foundation, OH, USA

Sudden Death in the Adult with Congenital Heart Disease Louise Harris, University Health Network, Toronto, ON, Canada

Coarctation Stent Treatment in Adults Thomas Forbes, Wayne State University, MI, USA

Management of Aortic Dilation in Congenital Heart Disease Angela T. Yetman, Primary Children's Medical Center, Salt Lake City, Utah, USA

## PEDIATRIC AND ADULT CONGENITAL HEART DISEASE MANAGEMENT (continued)

Update on Pediatric Mechanical Circulatory Support Brian W. Duncan, Cleveland Clinic, Cleveland, OH, USA

Catheter Laboratory Completion of the Fontan Operation Lee Benson, The Hospital for Sick Children, Toronto, Ontario, Canada

Interventional Decision Making in Adult Congenital Heart Disease *Eric Horlick*, Toronto General Hospital, Toronto, Canada

Percutaneous PFO Closure for Cryptogenic Stroke and Migraines, The Simple Way *Antonis Manolis*, Patras University, Athens, Greece

#### WHAT'S NEW IN CARDIOMYOPATHIES

Cardiomyopathies 2008: Recent Advances and Clinical Implications *Luisa Mestroni*, University of Colorado, Aurora, CO, USA

The Role of the Innate Immune Response in Protecting Against Infection of the Heart *Neil E. Bowles*, University of Utah School of Medicine, Salt Lake City, UT, USA

An Unappreciated Role for Ubiquitin Ligases in Experimental Cardiac Hypertrophy *Cam Patterson*, University of North Carolina at Chapel Hill, NC, USA

Doxorubicin Cardiotoxicity is Markedly Attenuated by Concurrent Treatment with Vincristine

Kanu Chatterjee, UCSF School of Medicine, San Francisco, CA, USA

Cardiovascular Effects of Chronic, Subclinical Exposure to Lipopolysaccharide *Wilbur Lew*, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA

#### Sepsis and the Heart

Marcos A. Rossi, University of Sao Paulo, Ribeirao Preto, S.P., BRAZIL

A Unique Clinical, Genetic and Morphological Features in Human Mitochondrial Cardiomyopathy *Teruhiko Toyo-Oka*, Tohoku University Bioengineering Research Organization, Sendai, Japan

Dilated Cardiomyopathy : Various Etiologies and Outcome Nodar N. Kipshidze, Acad. Nodar Kipshidze National Center of Therapy, Tbilisi, Georgia

Taco-Tsubo Cardiomyopathy Spyridon N. Koulouris, Evangelismos Hospital, Athens, Greece

Anemia in Heart Failure John N. Nanas, University of Athens, Greece

Unanswered Questions in Rheumatic Heart Disease Ganesan Karthikeyan, All India Institute of Medical Sciences, New Delhi, India

## HEART FAILURE: A WIDE SPECTRUM OF CLINICAL DILEMMAS

Obesity and Congestive Heart Failure Martin A. Alpert, University of Missouri School of Medicine, Columbia, MO, USA

Treatment of Cardiac Diseases: Evidence Based or Experience Based Medicine? *Wolfgang Kubler*, , Neckargemund, Germany

Dietary and Lifestyle Factors and Heart Failure Luc Djoussé, Harvard Medical School and Brigham & Women's Hospital, Boston, MA, USA

Recent Trends in Survival, Hospitalization and Treatment of Heart Failure *Paul A. Heidenreich*, Stanford University, Palo Alto, CA, USA

The African-American Heart Failure Trial: Scientific and Social Implications *Anne Taylor*, University of Minnesota Medical School, MN, USA

#### **DIASTOLIC FUNCTION**

Is Systolic Dysfunction Present in Diastolic Heart Failure? Insights Using Strain and Strain Rate Imaging *Hisham Dokainish,* Baylor College of Medicine, Houston, TX, USA

## PULMONARY HEART DISEASE

Right Ventricle – Specific Therapies in Pulmonary Hypertension and Heart Failure *Evangelos D. Michelakis*, University of Alberta, Edmonton, Alberta, Canada

#### PERICARDIAL DISEASE

Colchicine for Pericarditis: Hype or Hope? *Massimo Imazio,* Maria Vittoria Hospital, Torino, Italy

## **HEART FAILURE – NEW METHODS AND THERAPIES**

Differential Matrix Metalloproteinase Proteomic Profiling in Patients at Risk for Heart Failure: Diagnostic and Prognostic Implications? *Francis G. Spinale*, Medical University of South Carolina, Charleston, SC, USA

Healing and Remodeling After STEMI in the Elderly Bodh I. Jugdutt, University of Alberta Hospitals, Alberta Canada

New Therapies for Heart Failure Robert Hobbs, Cleveland Clinic, OH, USA

New Cardiac Enhancers for the Treatment of Acute Heart Failure Syndromes: Clinical Advantages and Drawbacks John Parissis, Attikon University Hospital, Athens, Greece

Treatment of Heart Failure with a Reduced Left Ventricular Ejection Fraction *Wilbert S. Aronow*, New York Medical College, Valhalla, NY, USA

Designing Non-RCT Studies like RCT Using Propensity Score Matching: Evidence for Diuretics, Hypokalemia, and Potassium Supplements in Chronic Heart Failure *Ali Ahmed*, University of Alabama at Birmingham, AL, USA

Only Large Reductions (>80%) in B-Type Natriuretic Peptide Levels (BNP and NT-ProBNP) are Predictive of Outcome in Ambulatory Chronic Heart Failure Patients *Wayne L. Miller*, Rochester Mayo Clinic, Rochester, MN, USA

Heart Failure Management Programmes: Which Interventions Work? *Finn Gustafsson*, University of Copenhagen, Copenhagen, Denmark

#### ADVANCED INTERVENTIONAL / SURGICAL THERAPIES FOR HEART FAILURE

Reconstruction of the Failing Left Ventricle with Intramyocardial Injections of Biopolymers Hani N. Sabbah, Henry Ford Hospital, Detroit, MI, USA

The Use of Cardiac Support Devices in the Treatment of Heart Failure : What Do We Know

Juan M. Aranda, University of Florida College of Medicine, Gainesville, FL, USA

Is There Still a Role for Mitral Valve Repair in Patients with End-Stage Heart Failure? *Dan M. Meyer*, University of Texas Southwestern Medical Center, Dallas, TX, USA

Percutaneous Interventions for Heart Failure Fayaz Shawl, Washington Adventist Hospital, Washington DC, USA

Permanent Mechanical Circulatory Support: Improved Technology and Outcomes *Mark S. Slaughter*, Advocate Christ Medical Center, Oak Lawn, IL, USA

Non Invasive Evaluation for Rejection in Heart Transplant Recipients using Leukocyte Gene Expression Daniel F. Pauly, University of Florida College of Medicine, Gainesville, FL, USA

#### **CONTROVERSIES IN CORONARY REVASCULARIZATION**

Revascularization vs Secondary Prevention: What to do when Two Worlds Collide *Gregory W. Barsness*, Mayo Clinic, Rochester, MN, USA

CABG is still the Best Therapy for Multivessel Coronary Artery Disease David P Taggart, John Radcliffe Hospital, Oxford, England

Chronic Ischemic Cardiomyopathy Complex - The Lociman Project in Cardiac Surgery *Roland Hetzer*, German Heart Institute, Berlin, Germany

#### HEART RATE, SYMPATHETIC / PARASYMPATHETIC TONE, ATHLETES

Heart Rate and Outcomes in Patient with Heart Disease Brian Olshansky, University of Iowa, Iowa City, IA, USA

Diurnal Rhythms: Unrecognized Critical Determinants of Cardiovascular Health and Disease *Michael J. Sole*, Toronto General Hospital, Toronto, ON, Canada

Sleep Apnea and the Heart Virend Somers, Mayo Clinic Rochester, MN, USA

Heart Rate - The Forgotten Risk Factor? Sandeep Gupta, Whipps Cross and St. Bartholomew's Hospitals, Leytonstone, UK

Update in Syncope Management. Applications of the New Guidelines Daniel Flammang, La Croix Rousse University Hospital, Saint Michel France

#### ELECTROPHYSIOLOGY, CARDIAC PACING AND DEFIBRILLATION

Role of Psychological Factors in Triggering Of Arrhythmias Rachel Lampert, Yale University School of Medicine, New Haven, CT, USA

Impact of Noninvasive Testing on Improving Identification of Patients Vulnerable to Sustained Ventricular Arrhythmias *Michael Cain* University at Buffalo School of Medicine & Biomedical Sciences, NY, USA

Psychosocial Adaptation and Quality-Of-Life in Patients with Pacemakers and Implantable Defibrillators *Firat Duru,* University Hospital of Zurich, Switzerland

Standard Pacing: Optimizing AV Delays Paul A. Levine, St. Jude Medical CRMD, Sylmar, CA, USA

Clinical Characteristics and Risk Stratification in Brugada Syndrome Masahiko Takagi, Osaka City University Graduate School of Medicine, Osaka, Japan

Long QT Syndrome: Should an ICD be used? James P. Daubert, University of Rochester Medical Center, Rochester, NY, USA

#### ELECTROPHYSIOLOGIC MANAGEMENT OF CHF-CRT AND BEYOND

Electrical Therapy for Heart Failure: What's New on the Horizon? Jagmeet P. Singh, Massachusetts General Hospital, Boston, MA, USA

How to Select the Appropriate Candidates for Cardiac Resynchronization Therapy? *Majid Haghjoo*, Iran University of Medical Sciences, Tehran, Iran

Cardiac Resynchronization Therapy in Heart Failure Patients: How To Predict Responders? *Mariavittoria H. Pitzalis*, Brody School of Medicine ECU, Greenville, NC, USA

Dyssynchrony in Diastolic Heart Failure Sherif F. Nagueh, Methodist DeBakey Heart Center, TX, USA

## MANAGEMENT OF ATRIAL FIBRILLATION

**Novel Mechanistic Insights into the Progression of Human Atrial Fibrillation Dobromir Dobrev**, Dresden University of Technology

Genetic Aspects of Atrial Fibrillation Jesper H. Svendsen, Rigshospitalet University Hospital Copenhagen, Denmark

New Advances in Echocardiography in Atrial Fibrillation Allan L. Klein, The Cleveland Clinic Foundation, Cleveland, OH, USA

Atrial Fibrillation: To Ablate or to Anticoagulate Alessandro Capucci, Hospital Guglielmo da Saliceto, Piacenza, Italy

Giving Rat Poison to Patients is Even More Dangerous than Previously Thought: A Re-Examination of Long-Term Warfarin Therapy *Peter Whittaker*, University of Massachusetts Medical School, Worcester, MA, USA

Ace Inhibitors, Statins, ARBS: Do they really prevent Atrial Fibrillation? Anne B. Curtis, University of South Florida, Tampa, FL, USA

New Antithrombotic Therapies for Stroke Prevention in Atrial Fibrillation *Greg Flaker*, University of Missouri, Columbia, MO, USA

New Oral Anticoagulants: The Future for Stroke Prevention in Atrial Fibrillation *Jeffrey Weitz*, Hendersen Research Center, Hamilton, Ontario, Canada

#### ABLATION OF ATRIAL FIBRILLATION AND ATRIAL FLUTTER

Ablation of Atrial Fibrillation – From Triggers to Substrate Dan Wichterle, General University Hospital, Prague, Czech Republic

Frequency Mapping of Complex Atrial Fractionated Electrograms (CAFE) During Atrial Fibrillation Edward Gerstenfeld, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Frequency Mapping and Ablation of Atrial Fibrillation Andreas Bollmann, Heart Center, Magdeburg, Germany

Long-Term Results in Catheter Ablation of Atrial Fibrillation *Fiorenzo Gaita*, Ospedale Cardinal Massaia, Asti, Italy

Electrophysiology and Ablation of Left Atrial Flutter Jose L. Merino, Hospital Universitario La Paz, Madrid, Spain

Long-Term Outcomes after Ablation of Atrial Flutter: A Meta-Analysis Mark A. Wood, Virginia Commonwealth University, Richmond, VA, USA

Emergence of Cryoablation as a Therapy for Atrial Fibrillation Peter G. Guerra, Montreal Heart Institute, Montreal, Quebec, Canada

Results of Concomitant Intraoperative Ablation to Treat Permanent Atrial Fibrillation *Thomas Deneke*, University of Bochum, Germany

Management after AF Ablation Daniela Husser, University Leipzig Heart Center, Leipzig, Germany